Join Growin Stock Community!

Biomea fusion, inc.BMEA.US Overview

US StockHealthcare
(No presentation for BMEA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BMEA AI Insights

BMEA Overall Performance

BMEA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BMEA Recent Performance

-0.12%

Biomea fusion, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BMEA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BMEA Key Information

BMEA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BMEA Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Price of BMEA

BMEA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.61
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.20
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.61
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.20
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BMEA's latest earnings report released?

    The most recent financial report for Biomea fusion, inc. (BMEA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BMEA's short-term business performance and financial health. For the latest updates on BMEA's earnings releases, visit this page regularly.

  • How much debt does BMEA have?

    As of the end of the reporting period, Biomea fusion, inc. (BMEA) had total debt of 6.88M, with a debt ratio of 0.12. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BMEA have?

    At the end of the period, Biomea fusion, inc. (BMEA) held Total Cash and Cash Equivalents of 47.01M, accounting for 0.85 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BMEA's EPS continuing to grow?

    According to the past four quarterly reports, Biomea fusion, inc. (BMEA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BMEA?

    Biomea fusion, inc. (BMEA)'s Free Cash Flow (FCF) for the period is -11.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 54.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

BMEA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1